John Green Net Worth

The estimated Net Worth of John L. Green is at least $257 Thousand dollars as of 6 July 2020. Mr. Green owns over 109,459 units of Unum Therapeutics stock worth over $257,229 and over the last 6 years he sold UMRX stock worth over $0. In addition, he makes $0 as Chief Financial Officer, Vice President - Finance, and Controller at Unum Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Green UMRX stock SEC Form 4 insiders trading

John has made over 1 trades of the Unum Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 109,459 units of UMRX stock worth $257,229 on 6 July 2020.

The largest trade he's ever made was exercising 109,459 units of Unum Therapeutics stock on 6 July 2020 worth over $257,229. On average, John trades about 21,892 units every 0 days since 2019. As of 6 July 2020 he still owns at least 109,459 units of Unum Therapeutics stock.

You can see the complete history of Mr. Green stock trades at the bottom of the page.

John Green biography

John L. Green serves as Chief Financial Officer, Vice President - Finance, Controller of the Company. He has served as our Principal Accounting Officer since January 2019. Prior to assuming the role of Principal Accounting Officer at Unum, he served as the Controller at Unum, responsible for financial operations. Prior to joining Unum, Mr. Green served as Principal Accounting Officer at Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, from March 2017 to June 2018. From November 2015 to March 2017 her served as the Controller at Fractyl Laboratories, Inc., a medical technology company. From June 2014 to November 2015, Mr. Green served as Director of Accounting at Dicerna Pharmaceuticals, Inc., a biopharmaceutical company. From November 2013 to June 2014, Mr. Green served as a Senior Manager at Corporate Finance Group, Inc., a financial consulting firm. From 2008 to September 2013, Mr. Green served as an Assurance Manager at PricewaterhouseCoopers LLP, an accounting firm. Mr. Green is a Chartered Professional Accountant and holds a B.S. in Chemistry and Biology from Acadia University.

How old is John Green?

John Green is 39, he's been the Chief Financial Officer, Vice President - Finance, and Controller of Unum Therapeutics since 2020. There are 5 older and 2 younger executives at Unum Therapeutics. The oldest executive at Unum Therapeutics, Inc. is Arlene Morris, 68, who is the Independent Director.

What's John Green's mailing address?

John's mailing address filed with the SEC is C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, SUITE 3100, CAMBRIDGE, MA, 02140.

Insiders trading at Unum Therapeutics

Over the last 7 years, insiders at Unum Therapeutics have traded over $0 worth of Unum Therapeutics stock and bought 1,283,156 units worth $11,122,392 . The most active insiders traders include Llc Fmr, Liam Ratcliffe, and Bruce Booth. On average, Unum Therapeutics executives and independent directors trade stock every 72 days with the average trade being worth of $286,216. The most recent stock trade was executed by Healthcare Capital Partners... on 14 August 2020, trading 451,000 units of UMRX stock currently worth $1,136,520.

What does Unum Therapeutics do?

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Complete history of Mr. Green stock trades at Unum Therapeutics

Unum Therapeutics executives and stock owners

Unum Therapeutics executives and other stock owners filed with the SEC include:

• Karen Ferrante,
  Independent Director
• Arlene Morris,
  Independent Director
• Matthew Ros,
  Independent Director
• Stephanie Ascher,
  Investor Relations
• Peter Harwin,
  Director
• Chris Cain,
  Director
• Jessica Sachs,
  Chief Medical Officer
• John Green,
  Chief Financial Officer, Vice President - Finance, Controller
• Andrew Robbins,
  President, Chief Executive Officer and Principal Executive Officer, Director
• Llc Fmr,
  
• Bruce Booth,
  Director
• Funds Management Llc Fairmount,
  10% owner
• Ltd Fil,
  
• Venture Fund Ix, L.P.Atlas ...,
  
• Liam Ratcliffe,
  Director
• Jorn Aldag,
  Director
• Robert J Perez,
  Director
• Seth Ettenberg,
  Chief Scientific Officer
• Geoffrey Hodge,
  Chief Technical Officer
• Charles Wilson,
  Chief Executive Officer
• Michael Vasconcelles,
  Chief Medical Officer
• Matthew Scott Osborne,
  Chief Financial Officer
• Healthcare Capital Partners...,